



Pakistan Journal of Neurological Sciences (PJNS)

Volume 8 | Issue 1

Article 4

1-2013

mucor mycosis: a fulminant case with extensive involvement and remarkable recovery

Asif SA

Liaquat National Hospital, Karachi, Pakistan

Follow this and additional works at: <http://ecommons.aku.edu/pjns>

 Part of the [Neurology Commons](#)

Recommended Citation

SA, Asif (2013) "mucor mycosis: a fulminant case with extensive involvement and remarkable recovery," *Pakistan Journal of Neurological Sciences (PJNS)*: Vol. 8: Iss. 1, Article 4.

Available at: <http://ecommons.aku.edu/pjns/vol8/iss1/4>

MUCOR MYCOSIS: A FULMINANT CASE WITH EXTENSIVE INVOLVEMENT AND REMARKABLE RECOVERY

Asif SA

Assistant Professor, Department of Neurology, Liaquat National Hospital, Karachi.

Correspondence to: Asif SA, Assistant Professor, Department of Neurology, Liaquat National Hospital, Karachi. Email: asif6991@yahoo.com

ABSTRACT

Mucor mycosis is a rare but fatal illness. It is seen in diabetics and immune compromised individuals. A case is presented with fulminant course, rapid progression and extensive involvement. He was treated with Fungizone and Itraconazole alongwith surgical debridement of infected nasal mucosa. Recommendation is made to increase the awareness of this fatal illness among local practitioners.

Keywords: Mucor mycosis, Fungizone, Diabetics.

INTRODUCTION

Mucor mycosis is a fatal fungal infection of nose that often invades brain. Intracranial spread can occur through the ophthalmic artery, superior fissure, or cribriform plate. The fungi invade the blood vessel lumina and cause thrombosis through inflammatory occlusion. Strong association with diabetes has been described. Mortality rates of 30-70% are quoted in literature. Survival rate declines when interval from diagnosis to treatment is more than 6 days.

A case is presented with widespread fulminant involvement. He was given dual antifungals and showed remarkable recovery with some residual deficit due to complication.

CASE REPORT

A 55yrs old male came to our outpatient for one day history of difficulty in use of right hand. Eight days earlier he had developed urticarial rashes all over the body. He was given some injectables by local general practitioner that relieved the symptoms. Three days later, he developed pain in left temple. Gradually left face became hard and swollen. Next morning he was not able to open left eye. Pain improved by some injectables given by local GP. There was no vomiting and he had remained afebrile throughout. Evening before admission, he developed weakness of right hand that brought him to hospital. He was diabetic and hypertensive for 5-6 years which was not very well controlled.

On examination he had a large swelling of left cheek, involving conjunctiva and eyelid.

His speech and gait was normal. Vision on left was limited to hand movement only. There was afferent pupillary defect on left side. Right pupil was 6mm round and reacting briskly to direct and very sluggishly to indirect stimulus. Left pupil was nonreacting at all. Left Masseters and Temporalis were normally contracting but there was decreased pain sensation on left V1 and V2 distribution. There was severe LMN type facial weakness on left. There was no hearing loss. Palate and Tongue were also normal. Shoulder abduction was 3+/5 on right but there was no movement at fingers. Power in left hand and both legs was normal. There was no gross difference in DTRs on the two sides. Plantars were both flexor. There was no loss of pain over the body and joint position sense was normal. On investigation Total leukocyte count was 18.7. ESR was 90mm/1st hr. Random blood sugar was 426mg%. Urea, creatinine and electrolytes were normal. Blood culture was negative for bacterial growth. CAT scan head and brain was unremarkable. MRI showed a small infarct in left parietal cortex. A large soft tissue swelling was also seen in left cheek extending upto the temple and into left orbit.

CAT scan cervical spine was normal. Endoscopic nasal examination showed black discoloration of left middle turbinate. Biopsy was taken. Fungal smear showed few aseptate fungal hyphae.

Diagnosis of Mucor Mycosis was made and Injection

Fungizone (Amphotericin B) 20mg was started that was later gradually increased to 80mg IV OD. Three days later, Cap ITRACONAZOLE 200mg BD was added. Over next one week swelling was seen to have regressed a little. After about 10 days of treatment he was sent for Endoscopic nasal debridement (FESS). There he became unconscious. When examined he was barely arousable. Two days later he opened eyes but was mute and his right side was moderately weak. Repeat MRI scan head showed occlusion of Left ICA with a big Left MCA territory infarct.

Antifungals were continued and Anti platelets were added. Renal and Hepatic functions were carefully monitored. Serum K⁺ used to be on lower side and was constantly replaced orally.

After 3 weeks of treatment he developed fever (102oF) and passed small amount of blood from right (opposite) nostril. Blood cultures and 5 sets of MPs were sent that were negative. A five day course of Cap. Ofloxacin 500mg was given. Fever subsided in three days. He never bled later on.

Amphotericin was held for two days during fever.

After one month of treatment nose was reexamined with rigid endoscope. Necrotic material and blood clots were seen that were removed and healthy mucosa came out.

Amphotericin was stopped after 5 weeks (total of 3.5Gm). Patient was discharged after 1½ months of stay. Itraconazole was continued for next 3 months.

He made a follow up visit in 5th month. Swelling was no more there. He had started to speak a few words. He could understand most of the things. He could follow complex commands and could express emotions. He could walk with unilateral support. There was total ophthalmoplegia in left eye and there was no vision.

DISCUSSION

First case of Mucor Mycosis was described by Paltauf in 1885¹. Since then little has changed in diagnosis and outcome of the disease². Mucor mycosis is a rare, often fatal fungal infection. It is caused by an aerobic saprophytic fungus belonging to the order mucorales and class zygomycetes. It is a common inhabitant of soil, decaying vegetation and can also be cultured from human nose, throat, oral cavity and stools. It typically originates in the nasal or oral mucosa, spreads to the paranasal sinuses and enters the orbit via the ethmoid and maxillary sinuses or via the nasolacrimal duct³. It

may also spread into the neck⁴. We had CT scan neck and cervical spread was ruled out.

Mucor mycosis is the third most common mycosis after candidiasis and aspergillosis. It is also now increasingly recognized in India, especially in patients with diabetes or trauma. Based on anatomic localization six forms have been described (1) Rhinocerebral, (2) Pulmonary, (3) Cutaneous, (4) Gastrointestinal, (5) Disseminated and (6) Uncommon presentations⁵. Isolated involvement of kidneys have also been reported⁶.

Our case was a diabetic and was not compliant of medicines. His illness started with some urticarial rash followed by headache alongwith swelling of left side of face. Perhaps the rashes were not associated with the Mucor infection because it subsided by local treatment most likely anti allergic or steroids, never recurred and when was examined after admission there was no skin involvement. He continued to go to local practitioner who could not realize the gravity of situation. It was finally the weakness of right hand that brought him to us. He had involvement of multiple cranial nerves of one side. The suspicion was high about that been mucor⁷. MRI scan showed a soft tissue mass in the left facial area. It was seen involving the orbit and the nasal cavity too. In addition a small infarct in the superior parietal area was seen describing the weakness of hand. Association of mucor with stroke has been described⁸.

The overall survival rate of patients with mucormycosis is approximately 50%. Rhinocerebral mucormycosis has a higher survival rate than does pulmonary or disseminated mucormycosis⁹.

Rhinocerebral mucormycosis requires urgent extensive and repeated debridements to remove all the fungal debris and involved tissue along with antifungal therapy on suspicion of the diagnosis¹⁰. Current data supports the first-line use of high-dose liposomal amphotericin B for mucormycosis, particularly for cases of central nervous system disease, with amphotericin B lipid complex serving as a reasonable second-line agent. A cumulative dose of at least 3 g of amphotericin B is recommended to treat rhinocerebral phycomycosis¹¹. Currently, novel regimens for the treatment of mucormycosis include combination of lipid-based amphotericin plus either an echinocandin or itraconazole or both¹².

Our patient underwent surgical debridement of the nasal infection. It was associated with the combination



Figure 1: Huge swelling Left cheek (with permission)




Figure 2: Small Left superior parietal cortical infarct.




Figure 3: Huge swelling of soft tissue in left cheek eye and nose




Figure 4: CT scan cervical region did not show any extension of the mass into the neck.




Figure 5: Repeat MRI scan showing major left MCA infarct.



Figure 6: Follow up visit after five months showing remarkable recovery. (with permission)

of Fungizone (total of 3.2 Gm was given) and Itracozazole (continued for 3 months). He had started to show signs of improvement during hospital stay. The size of the facial swelling started regressing. Unfortunately he developed a large MCA infarct on left side. Treatment, however, was continued. In the follow up visit there was complete subsidence of swelling although he had lost the eye and facial weakness was permanent.

CONCLUSION

High index of suspicion is required to prevent complications as the course of the disease is very rapid. Awareness among the local practitioners is recommended as in our case the local practitioner could not recognize the illness and kept on treating symptomatically.

REFERENCES

1. Paltauf A. Mucormycosis mucorina. Virchows Arch Pathol Anat 1885;102:543-64.
2. Bell S, Mahoney L. Mucormycosis: a case study. Crit Care Nurse 2000 Feb;20(1):18-23.
3. Hosseini SM, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol 2005;262:932-8.
4. Chacko B, Ananthakrishna R, Vasuki Z et al. Mucormycosis isolated from perilymphatic tissue: An unusual presentation. Journal of Postgraduate Medicine; Vol. 52, No. 4, October-December, 2006: 294-295
5. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012 Feb;54 Suppl 1:S23-34.
6. Ritu Verma, Mukul Vij, Vinita Agrawal et al. Renal mucormycosis in immunocompetent patients: Report of three cases Basic and Applied Pathology 2011; 4: 66-70
7. Mutsukura K, Tsuboi Y, Imamura A et al. Garcin syndrome in a patient with rhinocerebral mucormycosis. No To Shinekei 2004 Mar; 56(3):231-5
8. Thajeb P, Thajeb T, Dai D. Fatal strokes in patients with rhino-orbito-cerebral mucormycosis and associated vasculopathy. Scand J Infect Dis. 2004;36(9):643-8.
9. Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine 1986;65:113-123.
10. Shraddha J, Sunil K, Amit KI. Rhinocerebral Mucormycosis with Isolated Sixth Nerve Palsy in An Immunocompetent Patient Med J Malaysia;Vol 66 No 4 October 2011: 376-8
11. Mubashir I, Moghira I, Mohammad AK et al. Rhino cerebral Zygomycosis in Pakistan: Clinical Spectrum, Management, and Outcome JPMA 2011;61:477
12. Brad Spellberg, John Edwards Jr, Ashraf Ibrahim. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. July 2005 vol. 18 no. 3 556- 569.